Ibrutinib, a BCR-signaling inhibitor which is under clinical trials for several hematologic malignancies could be a potential compound for inhibition of MYC induced proliferation in B-cell malignancies [NCT02303392]. This evidence concerns the gene BCR and hematologic disorder.